Nonprofit Acquires Abandoned Leukemia Drug Supply.

Blood Cancer United secures remaining luveltamab tazevibulin supply to support compassionate use for children with a rare AML.

• Why it matters: This highlights the ongoing funding challenges in pediatric cancer drug development, emphasizing the need for alternative approaches to access and sustain treatments.
• What they did: The nonprofit acquired the remaining drug supply and plans to continue the compassionate use program for children with a rare form of AML.
• The result: This action may improve access to experimental treatments for affected children and underscores the importance of nonprofit efforts in addressing pediatric cancer treatment gaps.